Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

India's Gland Pharma jumps 23% in market debut

11/20/2020 | 03:48am EST
FILE PHOTO: A broker reacts while trading at his computer terminal at a stock brokerage firm in Mumbai

BENGALURU (Reuters) - Shares of India's Gland Pharma got off to a flying start in their market debut on Friday, rising as much as 23% and highlighting a strong appetite for drug stocks.

The Hyderabad-based company opened at 1,710 rupees per share, after its stock was priced at 1,500 rupees in India's largest initial public offering by a drugmaker, giving it a market value of 279.21 billion rupees.

Pharma stocks are on a tear this year, with the Nifty Pharma Index up nearly 44%, far outpacing the 5% rise in the benchmark NSE Nifty 50 index.

Growth in the Indian pharmaceutical market bounced back to pre-pandemic levels in October, helped by cardiac, gastroenterology and dermatology markets, Prabhudas Lilladher analysts said in a note on Tuesday.

Established in 1978 and backed by China-based Shanghai Fosun Pharmaceutical Group Co Ltd, Gland Pharma makes injectable generic drugs and sells its products in over 60 countries.

"(Gland) has never received a negative USFDA report. The future prospects are bright as it has 267 ANDA filings of which 215 are approved," said Hemang Jani, equity strategy head, broking and distribution, at Motilal Oswal Financial Services Ltd.

The company offered 43.2 million shares in the IPO, including a fresh issue of 8.3 million shares, the proceeds from which will be used to fund capital expenditure needs. It raised 64.80 billion rupees ($873.79 million).

For the year ended March 31, Gland posted https://www.sebi.gov.in/filings/public-issues/nov-2020/gland-pharma-limited-prospectus_48166.html a profit of 7.73 billion rupees and revenue from operations of 26.33 billion rupees.

Some of Gland's customers include companies such as Novo Nordisk and Viatris, John Christopher, practice head of business intelligence, pharma, at GlobalData told Reuters.

Kotak Mahindra Capital, Citigroup Global Markets India and Nomura Financial Advisory and Securities (India) were among the lead book runners for Gland's IPO.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Anil D'Silva)

By Anuron Kumar Mitra


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CITIGROUP INC. -0.68% 56.67 Delayed Quote.-29.07%
GLOBALDATA PLC -0.20% 1497 Delayed Quote.16.28%
MOTILAL OSWAL FINANCIAL SERVICES LIMITED 0.59% 609.3 Delayed Quote.-19.77%
NIFTY 50 -0.14% 12968.95 Delayed Quote.6.73%
NOMURA CO., LTD. -1.76% 780 End-of-day quote.-46.39%
NOMURA HOLDINGS, INC. -0.35% 536.6 End-of-day quote.-4.76%
NOVO NORDISK A/S 1.09% 419.25 Delayed Quote.8.43%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. -2.94% 51.59 End-of-day quote.93.95%
All news about SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
11/26BIONTECH : and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Le..
AQ
11/26SHANGHAI FOSUN PHARMACEUTICAL : BioNTech and Fosun Pharma Announce the Start of ..
PU
11/25SHANGHAI FOSUN PHARMACEUTICAL : Plan in relation to the proposed non-public issu..
PU
11/25BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China
RE
11/20SHANGHAI FOSUN PHARMACEUTICAL : Update on the proposed spin-off and separate lis..
PU
11/20India's Gland Pharma jumps 23% in market debut
RE
11/17BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candi..
AQ
11/13China approves Shanghai Fosun's unit to run human testing for BioNTech's COVI..
RE
11/11SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
11/11China's Rhodiola set to sell and test Russia's Sputnik-V vaccine
RE
More news
Financials
Sales 2020 32 812 M 4 988 M 4 988 M
Net income 2020 3 531 M 537 M 537 M
Net Debt 2020 14 857 M 2 259 M 2 259 M
P/E ratio 2020 37,8x
Yield 2020 0,84%
Capitalization 104 B 15 778 M 15 771 M
EV / Sales 2020 3,61x
EV / Sales 2021 3,08x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 41,59 CNY
Last Close Price 51,59 CNY
Spread / Highest target 35,0%
Spread / Average Target -19,4%
Spread / Lowest Target -58,4%
EPS Revisions
Managers
NameTitle
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman
Sector and Competitors